logo

For the Inventor, By the Inventor

Basel, Switzerland

Vaximm Ag


USPTO Granted Patents = 9



Forward Citations = 28

Loading Chart...
Loading Chart...

4 inventors (with patents filed for the assignee):

goldMedal Heinz Lubenau (9 out of 15 patents)

silverMedal Marco Springer (3 out of 4 patents)

bronzeMedal Holger Siede (1 out of 1 patent)

4.  Renate Janssen (1 out of 1 patent)


9 patents:

1. 11357842 - PD-L1 targeting DNA vaccine for cancer immunotherapy (2022-06-14),
2. 10980868 - VEGFR-2 targeting immunotherapy approach (2021-04-20),
3. 10905752 - VEGFR-2 targeting DNA vaccine for combination therapy (2021-02-02),
4. 10821163 - Process for the production of a DNA vaccine for cancer immunotherapy (2020-11-03),
5. 10815455 - Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1 (2020-10-27),
6. 10293037 - DNA vaccine for use in pancreatic cancer patients (2019-05-21),
7. 9920297 - [object Object] (2018-03-20),
8. 9493738 - [object Object] (2016-11-15),
9. 9415098 - DNA vaccine for use in pancreatic cancer patients (2016-08-16),
Vaximm Ag is a clinical-stage biotechnology company that focuses on developing oral T-cell immunotherapies for patients suffering from cancer. The company's lead product candidate, VXM01, is designed to stimulate the patient's immune system to attack tumor cells. Vaximm's innovative approach to cancer treatment has shown promising results in clinical trials, making it a pioneering player in the field of immunotherapy.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

9 Patents

#35 in Basel

#1,095 in Switzerland

...
Basel, Switzerland

Vaximm Ag

Forward Citations = 28

4 inventors:

goldMedal Heinz Lubenau (9 out of 15 patents)

silverMedal Marco Springer (3 out of 4 patents)

bronzeMedal Holger Siede (1 out of 1 patent)

4.  Renate Janssen (1 out of 1 patent)

Please report any incorrect information to support@idiyas.com
Loading…